363 related articles for article (PubMed ID: 16843266)
21. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
22. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW; Druker BJ
Oncogene; 2015 Jun; 34(23):2991-9. PubMed ID: 25109334
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
24. JAK protein kinase inhibitors.
Thompson JE
Drug News Perspect; 2005 Jun; 18(5):305-10. PubMed ID: 16193102
[TBL] [Abstract][Full Text] [Related]
25. Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia.
Rajasingh J; Raikwar HP; Muthian G; Johnson C; Bright JJ
Biochem Biophys Res Commun; 2006 Feb; 340(2):359-68. PubMed ID: 16364242
[TBL] [Abstract][Full Text] [Related]
26. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
Mohi MG; Boulton C; Gu TL; Sternberg DW; Neuberg D; Griffin JD; Gilliland DG; Neel BG
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3130-5. PubMed ID: 14976243
[TBL] [Abstract][Full Text] [Related]
27. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain.
Mella P; Schumacher RF; Cranston T; de Saint Basile G; Savoldi G; Notarangelo LD
Hum Mutat; 2001 Oct; 18(4):355-6. PubMed ID: 11668621
[TBL] [Abstract][Full Text] [Related]
28. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
29. Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha.
Ohashi A; Kinoshita K; Isozaki K; Nishida T; Shinomura Y; Kitamura Y; Hirota S
Int J Cancer; 2004 Sep; 111(3):317-21. PubMed ID: 15221957
[TBL] [Abstract][Full Text] [Related]
30. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
31. [Experimental research on tyrosine-kinase inhibitor STI571 and P21WAF gene clone to treat chronic myeloid leukemia].
Wang W; Sun BZ; Liu XP; Feng Q; Shang ZC; Cao YX; Yao LB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):737-42. PubMed ID: 15631651
[TBL] [Abstract][Full Text] [Related]
32. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
33. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases.
Takahashi T; Shirasawa T
FEBS Lett; 1994 Apr; 342(2):124-8. PubMed ID: 8143863
[TBL] [Abstract][Full Text] [Related]
34. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.
Kim BH; Jee JG; Yin CH; Sandoval C; Jayabose S; Kitamura D; Bach EA; Baeg GH
Mol Cancer; 2010 Feb; 9():36. PubMed ID: 20149240
[TBL] [Abstract][Full Text] [Related]
35. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
[TBL] [Abstract][Full Text] [Related]
36. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
[TBL] [Abstract][Full Text] [Related]
37. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.
Tyner JW; Walters DK; Willis SG; Luttropp M; Oost J; Loriaux M; Erickson H; Corbin AS; O'Hare T; Heinrich MC; Deininger MW; Druker BJ
Blood; 2008 Feb; 111(4):2238-45. PubMed ID: 18025156
[TBL] [Abstract][Full Text] [Related]
38. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
39. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.
Chen M; Cheng A; Candotti F; Zhou YJ; Hymel A; Fasth A; Notarangelo LD; O'Shea JJ
Mol Cell Biol; 2000 Feb; 20(3):947-56. PubMed ID: 10629052
[TBL] [Abstract][Full Text] [Related]
40. Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.
Rivera-Munoz P; Laurent AP; Siret A; Lopez CK; Ignacimouttou C; Cornejo MG; Bawa O; Rameau P; Bernard OA; Dessen P; Gilliland GD; Mercher T; Malinge S
Blood Adv; 2018 Jul; 2(13):1616-1627. PubMed ID: 29986854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
